Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2000

View Archived Issues

Nissin grants Immune Network license to antibody for HIV treatment

CardioGene and Intracardia merge

Phytopharm begins phase II trial of P-45 for alopecia areata

AltaRex and Dompe establish OvaRex alliance for Europe

Copromotion agreement for Vestra terminated by Pharmacia and Janssen

Shire reports major launch for Reminyl

SciClone initiates Zadaxin trial for malignant melanoma in Australia

Clinical evaluation begins for QS-21-containing flu vaccine

Lead candidate selected in Roche/Vernalis obesity collaboration

Aurora Biosciences to acquire PanVera

Company Profile: Allos Therapeutics

CI-1042 shows biological activity in refractory head and neck cancer

Human Genome Sciences reports third quarter highlights

Company Profile: Affina Immuntechnik

Potent new antiplatelet agent synthesized at Welfide acts as 5-HT2 receptor antagonist

Cardioselective antimuscarinic agent MF-10058 in development for cardiac conduction disorders

Quinolone derivative exerts significant inotropic/vasodilating effects

Promising candidate for asthma, COPD therapy characterized by Pfizer researchers

Oncologic Drugs Advisory Committee meeting in mid-December has a full agenda

First clinical results for Perceptin discussed at Sendai symposium

Antitumor agents from Spanish university induce apoptosis

Preparation and use of new MMP/TNF-alpha inhibitors described by Fujisawa

Novel, steroidal, tissue-selective estrogens disclosed by Schering AG

SB presents new series with inhibitory activity against essential bacterial enzyme

Lilly identifies a number of peptides with antifungal activity

Hydroxamic acid-based MMP inhibitors discovered by Sumitomo team

New cognition-enhancing series described in recent patent by ADIR